Optimizing PCSK9 Inhibitor Integration for Cardiovascular Disease Management in Pakistan.

Area of Science:

• Cardiology
• Pharmacoeconomics
• Public Health

Background:

• Cardiovascular diseases (CVDs), including Coronary Artery Disease (CAD) and Ischemic Heart Disease (IHD), represent a significant global health challenge with increasing prevalence in Pakistan.
• While PCSK9 inhibitors demonstrate efficacy in reducing LDL cholesterol and cardiovascular risk, traditional treatments remain crucial.

Purpose of the Study:

• To examine the challenges in accessing PCSK9 inhibitors in Pakistan, considering financial constraints and limited healthcare resources.
• To highlight the need for multi-stakeholder collaboration to ensure affordability and equitable access to PCSK9 inhibitors.

Main Methods:

• The study reviews existing literature and health economic data pertaining to PCSK9 inhibitor access in low-resource settings.
• It analyzes the impact of high drug costs on patient accessibility within the Pakistani healthcare system.

Main Results:

• Access to PCSK9 inhibitors in Pakistan is severely restricted by their high cost, exacerbating existing healthcare resource limitations.
• Significant financial and logistical hurdles prevent widespread adoption of these advanced therapies.

Conclusions:

• Urgent, collaborative efforts involving government, the healthcare sector, and pharmaceutical companies are necessary to address the affordability and accessibility of PCSK9 inhibitors.
• Further research specific to Pakistan and integration into standard treatment protocols are essential for improving cardiovascular care.